{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T23:53:18Z","timestamp":1785196398608,"version":"3.55.0"},"reference-count":107,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100004826","name":"Beijing Natural Science Foundation","doi-asserted-by":"publisher","award":["7242211"],"award-info":[{"award-number":["7242211"]}],"id":[{"id":"10.13039\/501100004826","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82174056"],"award-info":[{"award-number":["82174056"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ajp.amjpathol.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of Pathology"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.ajpath.2025.08.005","type":"journal-article","created":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T15:36:36Z","timestamp":1757604996000},"page":"2258-2273","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["From Theory to Practice"],"prefix":"10.1016","volume":"195","author":[{"given":"Han","family":"Gao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongli","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiufeng","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fulei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiru","family":"Ba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiatong","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7215-053X","authenticated-orcid":false,"given":"Chengwei","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuzi","family":"Xin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohui","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guowei","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ajpath.2025.08.005_bib1","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.ejso.2007.04.002","article-title":"Appendiceal neoplasms and pseudomyxoma peritonei: a population based study","volume":"34","author":"Smeenk","year":"2008","journal-title":"Eur J Surg Oncol"},{"key":"10.1016\/j.ajpath.2025.08.005_bib2","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1067\/j.cpsurg.2008.04.003","article-title":"Pseudomyxoma peritonei","volume":"45","author":"Smeenk","year":"2008","journal-title":"Curr Probl Surg"},{"key":"10.1016\/j.ajpath.2025.08.005_bib3","doi-asserted-by":"crossref","first-page":"3531","DOI":"10.3748\/wjg.v17.i30.3531","article-title":"Histological origin of pseudomyxoma peritonei in Chinese women: clinicopathology and immunohistochemistry","volume":"17","author":"Guo","year":"2011","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.ajpath.2025.08.005_bib4","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1002\/1096-9098(200012)75:4<270::AID-JSO9>3.0.CO;2-V","article-title":"Unusual origins of Pseudomyxoma peritonei","volume":"75","author":"de Bree","year":"2000","journal-title":"J Surg Oncol"},{"key":"10.1016\/j.ajpath.2025.08.005_bib5","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/0016-5085(86)90094-6","article-title":"Pseudomyxoma peritonei associated with colloid carcinoma of the pancreas","volume":"90","author":"Chejfec","year":"1986","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ajpath.2025.08.005_bib6","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1097\/00000478-200305000-00008","article-title":"Mucinous tumors arising in ovarian mature cystic teratomas: relationship to the clinical syndrome of pseudomyxoma peritonei","volume":"27","author":"Ronnett","year":"2003","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.ajpath.2025.08.005_bib7","doi-asserted-by":"crossref","first-page":"2799","DOI":"10.1245\/s10434-014-4336-8","article-title":"Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy for pseudomyxoma peritonei arising from urachus","volume":"22","author":"Liu","year":"2015","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.ajpath.2025.08.005_bib8","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1007\/s00104-022-01696-7","article-title":"[Current treatment recommendations for pseudomyxoma peritonei]","volume":"93","author":"Leebmann","year":"2022","journal-title":"Chirurgie (Heidelb)"},{"key":"10.1016\/j.ajpath.2025.08.005_bib9","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1007\/978-1-4613-1247-5_23","article-title":"Clinical research methodologies in diagnosis and staging of patients with peritoneal carcinomatosis","volume":"82","author":"Jacquet","year":"1996","journal-title":"Cancer Treat Res"},{"key":"10.1016\/j.ajpath.2025.08.005_bib10","doi-asserted-by":"crossref","first-page":"2449","DOI":"10.1200\/JCO.2011.39.7166","article-title":"Early- and long-term outcome data of patients with pseudomyxoma peritonei from appendiceal origin treated by a strategy of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy","volume":"30","author":"Chua","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ajpath.2025.08.005_bib11","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/S1055-3207(03)00026-7","article-title":"The etiology, clinical presentation, and management of pseudomyxoma peritonei","volume":"12","author":"Moran","year":"2003","journal-title":"Surg Oncol Clin N Am"},{"key":"10.1016\/j.ajpath.2025.08.005_bib12","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1097\/00000478-199512000-00006","article-title":"Disseminated peritoneal adenomucinosis and peritoneal mucinous carcinomatosis: a clinicopathologic analysis of 109 cases with emphasis on distinguishing pathologic features, site of origin, prognosis, and relationship to \"pseudomyxoma peritonei.\"","volume":"19","author":"Ronnett","year":"1995","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.ajpath.2025.08.005_bib13","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1097\/01.pas.0000202039.74837.7d","article-title":"Pseudomyxoma peritonei of appendiceal origin: a clinicopathologic analysis of 101 patients uniformly treated at a single institution, with literature review","volume":"30","author":"Bradley","year":"2006","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.ajpath.2025.08.005_bib14","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.ctrv.2006.11.001","article-title":"Pseudomyxoma peritonei","volume":"33","author":"Smeenk","year":"2007","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.ajpath.2025.08.005_bib15","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1097\/PAS.0000000000000535","article-title":"A consensus for classification and pathologic reporting of pseudomyxoma peritonei and associated appendiceal neoplasia: the results of the Peritoneal Surface Oncology Group International (PSOGI) modified Delphi process","volume":"40","author":"Carr","year":"2016","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.ajpath.2025.08.005_bib16","series-title":"Digestive system tumours. WHO Classification of Tumours","first-page":"144","year":"2019"},{"key":"10.1016\/j.ajpath.2025.08.005_bib17","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1245\/s10434-007-9691-2","article-title":"Pseudomyxoma peritonei: clinical pathological and biological prognostic factors in patients treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC)","volume":"15","author":"Baratti","year":"2008","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.ajpath.2025.08.005_bib18","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1111\/apm.12653","article-title":"Carbonic anhydrase II: a novel biomarker for pseudomyxoma peritonei","volume":"125","author":"Jarvinen","year":"2017","journal-title":"APMIS"},{"key":"10.1016\/j.ajpath.2025.08.005_bib19","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1097\/SLA.0b013e31818eec64","article-title":"Pseudomyxoma peritonei: biological features are the dominant prognostic determinants after complete cytoreduction and hyperthermic intraperitoneal chemotherapy","volume":"249","author":"Baratti","year":"2009","journal-title":"Ann Surg"},{"key":"10.1016\/j.ajpath.2025.08.005_bib20","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1038\/sj.bjc.6603398","article-title":"A specific cadherin phenotype may characterise the disseminating yet non-metastatic behaviour of pseudomyxoma peritonei","volume":"95","author":"Bibi","year":"2006","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ajpath.2025.08.005_bib21","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.humpath.2016.02.022","article-title":"Expression of CEA, CA19-9, CA125, and EpCAM in pseudomyxoma peritonei","volume":"54","author":"Nummela","year":"2016","journal-title":"Hum Pathol"},{"key":"10.1016\/j.ajpath.2025.08.005_bib22","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1111\/j.1365-2559.2006.02512.x","article-title":"CDX-2 expression in pseudomyxoma peritonei: a clinicopathological study of 42 cases","volume":"49","author":"Nonaka","year":"2006","journal-title":"Histopathology"},{"key":"10.1016\/j.ajpath.2025.08.005_bib23","doi-asserted-by":"crossref","DOI":"10.1177\/03000605211022297","article-title":"Prognostic significance of CEA, Ki67 and p53 in pseudomyxoma peritonei of appendiceal origin","volume":"49","author":"Yan","year":"2021","journal-title":"J Int Med Res"},{"key":"10.1016\/j.ajpath.2025.08.005_bib24","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.0260","article-title":"Serum tumor markers and outcomes in patients with appendiceal adenocarcinoma","volume":"7","author":"Yousef","year":"2024","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.ajpath.2025.08.005_bib25","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.594763","article-title":"Prognostic value of CEA, CA19-9, CA125, CA724, and CA242 in serum and ascites in pseudomyxoma peritonei","volume":"11","author":"Liang","year":"2021","journal-title":"Front Oncol"},{"key":"10.1016\/j.ajpath.2025.08.005_bib26","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.jss.2022.01.001","article-title":"Prognostic impact of pathology, cytoreduction, and tumor markers in pseudomyxoma peritonei","volume":"274","author":"Lopes","year":"2022","journal-title":"J Surg Res"},{"key":"10.1016\/j.ajpath.2025.08.005_bib27","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1186\/s12885-023-10545-7","article-title":"Serum and ascites tumor markers in the diagnostic and prognostic prediction for appendiceal pseudomyxoma peritonei","volume":"23","author":"Wang","year":"2023","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ajpath.2025.08.005_bib28","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.3390\/cancers15041326","article-title":"Prognostic factors in pseudomyxoma peritonei with emphasis on the predictive role of peritoneal cancer index and tumor markers","volume":"15","author":"Blaj","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ajpath.2025.08.005_bib29","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1007\/s00268-013-1988-7","article-title":"Preoperative carcinoembryonic antigen level predicts prognosis in patients with pseudomyxoma peritonei treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy","volume":"37","author":"Canbay","year":"2013","journal-title":"World J Surg"},{"key":"10.1016\/j.ajpath.2025.08.005_bib30","doi-asserted-by":"crossref","first-page":"2299","DOI":"10.1016\/j.ejso.2017.09.009","article-title":"CA 19-9 to peritoneal carcinomatosis index (PCI) ratio is prognostic in patients with epithelial appendiceal mucinous neoplasms and peritoneal dissemination undergoing cytoreduction surgery and intraperitoneal chemotherapy: a retrospective cohort study","volume":"43","author":"Kozman","year":"2017","journal-title":"Eur J Surg Oncol"},{"key":"10.1016\/j.ajpath.2025.08.005_bib31","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/j.jmoldx.2018.05.002","article-title":"Analysis of mutation and loss of heterozygosity by whole-exome sequencing yields insights into pseudomyxoma peritonei","volume":"20","author":"Pengelly","year":"2018","journal-title":"J Mol Diagn"},{"key":"10.1016\/j.ajpath.2025.08.005_bib32","doi-asserted-by":"crossref","first-page":"E282","DOI":"10.1002\/ijc.29245","article-title":"Genomic profile of pseudomyxoma peritonei analyzed using next-generation sequencing and immunohistochemistry","volume":"136","author":"Nummela","year":"2015","journal-title":"Int J Cancer"},{"key":"10.1016\/j.ajpath.2025.08.005_bib33","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1038\/bjc.2013.47","article-title":"Frequent GNAS mutations in low-grade appendiceal mucinous neoplasms","volume":"108","author":"Nishikawa","year":"2013","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ajpath.2025.08.005_bib34","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1002\/cam4.542","article-title":"Molecular profiles of high-grade and low-grade pseudomyxoma peritonei","volume":"4","author":"Noguchi","year":"2015","journal-title":"Cancer Med"},{"key":"10.1016\/j.ajpath.2025.08.005_bib35","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/j.prp.2015.06.004","article-title":"A mutation spectrum that includes GNAS, KRAS and TP53 may be shared by mucinous neoplasms of the appendix","volume":"211","author":"Hara","year":"2015","journal-title":"Pathol Res Pract"},{"key":"10.1016\/j.ajpath.2025.08.005_bib36","doi-asserted-by":"crossref","first-page":"2179","DOI":"10.1007\/s00432-020-03321-8","article-title":"The biological basis and function of GNAS mutation in pseudomyxoma peritonei: a review","volume":"146","author":"Lin","year":"2020","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1016\/j.ajpath.2025.08.005_bib37","doi-asserted-by":"crossref","first-page":"106888","DOI":"10.18632\/oncotarget.22455","article-title":"Targeting G-protein coupled receptor-related signaling pathway in a murine xenograft model of appendiceal pseudomyxoma peritonei","volume":"8","author":"Dilly","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.ajpath.2025.08.005_bib38","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1016\/j.ccr.2012.04.024","article-title":"Oncogenic Kras-induced GM-CSF production promotes the development of pancreatic neoplasia","volume":"21","author":"Pylayeva-Gupta","year":"2012","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ajpath.2025.08.005_bib39","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0073616","article-title":"Differential expression of IL-17, 22 and 23 in the progression of colorectal cancer in patients with K-ras mutation: Ras signal inhibition and crosstalk with GM-CSF and IFN-gamma","volume":"8","author":"Petanidis","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.ajpath.2025.08.005_bib40","doi-asserted-by":"crossref","first-page":"S191","DOI":"10.21037\/jgo-20-136","article-title":"Omics analyses in peritoneal metastasis-utility in the management of peritoneal metastases from colorectal cancer and pseudomyxoma peritonei: a narrative review","volume":"12","author":"Lund-Andersen","year":"2021","journal-title":"J Gastrointest Oncol"},{"key":"10.1016\/j.ajpath.2025.08.005_bib41","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1186\/s40164-023-00465-4","article-title":"Antitumor effect of a small-molecule inhibitor of KRAS(G12D) in xenograft models of mucinous appendicular neoplasms","volume":"12","author":"Vazquez-Borrego","year":"2023","journal-title":"Exp Hematol Oncol"},{"key":"10.1016\/j.ajpath.2025.08.005_bib42","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1007\/s10555-023-10088-0","article-title":"The genetic profile and molecular subtypes of human pseudomyxoma peritonei and appendiceal mucinous neoplasms: a systematic review","volume":"42","author":"Murage","year":"2023","journal-title":"Cancer Metastasis Rev"},{"key":"10.1016\/j.ajpath.2025.08.005_bib43","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1177\/000313481307901120","article-title":"Proposed classification of pseudomyxoma peritonei: influence of signet ring cells on survival","volume":"79","author":"Shetty","year":"2013","journal-title":"Am Surg"},{"key":"10.1016\/j.ajpath.2025.08.005_bib44","doi-asserted-by":"crossref","first-page":"4082","DOI":"10.1158\/1078-0432.CCR-23-4072","article-title":"Precision oncology and systemic targeted therapy in pseudomyxoma peritonei","volume":"30","author":"Martinez-Quintanilla","year":"2024","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ajpath.2025.08.005_bib45","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.humpath.2018.11.011","article-title":"Heterogeneous mutational profile and prognosis conferred by TP53 mutations in appendiceal mucinous neoplasms","volume":"85","author":"Zhu","year":"2019","journal-title":"Hum Pathol"},{"key":"10.1016\/j.ajpath.2025.08.005_bib46","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1002\/jso.26114","article-title":"Investigating the utility of extended mutation analysis in gastrointestinal peritoneal metastasis","volume":"122","author":"Foster","year":"2020","journal-title":"J Surg Oncol"},{"key":"10.1016\/j.ajpath.2025.08.005_bib47","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1007\/s00428-020-02906-5","article-title":"Molecular and clinicopathological features of appendiceal mucinous neoplasms","volume":"478","author":"Yanai","year":"2021","journal-title":"Virchows Arch"},{"key":"10.1016\/j.ajpath.2025.08.005_bib48","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1158\/1541-7786.MCR-22-0801","article-title":"Whole-exome sequencing identifies mutation profile and mutation signature-based clustering associated with prognosis in appendiceal pseudomyxoma peritonei","volume":"22","author":"Lin","year":"2024","journal-title":"Mol Cancer Res"},{"key":"10.1016\/j.ajpath.2025.08.005_bib49","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.1097\/PAS.0b013e3182299c25","article-title":"Determining the site of origin of mucinous adenocarcinoma: an immunohistochemical study of 175 cases","volume":"35","author":"Chu","year":"2011","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.ajpath.2025.08.005_bib50","doi-asserted-by":"crossref","first-page":"7517","DOI":"10.1245\/s10434-023-13721-y","article-title":"Targeted next-generation sequencing improves the prognostication of patients with disseminated appendiceal mucinous neoplasms (pseudomyxoma peritonei)","volume":"30","author":"Wald","year":"2023","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.ajpath.2025.08.005_bib51","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.3390\/biomedicines11072049","article-title":"A2AR expression and immunosuppressive environment independent of KRAS and GNAS mutations in pseudomyxoma peritonei","volume":"11","author":"Kusamura","year":"2023","journal-title":"Biomedicines"},{"key":"10.1016\/j.ajpath.2025.08.005_bib52","doi-asserted-by":"crossref","DOI":"10.1002\/cam4.70340","article-title":"Targeted genetic sequencing analysis of 223 cases of pseudomyxoma peritonei treated by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy shows survival related to GNAS and KRAS status","volume":"13","author":"Gibson","year":"2024","journal-title":"Cancer Med"},{"key":"10.1016\/j.ajpath.2025.08.005_bib53","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/j.humpath.2009.12.013","article-title":"Exploring the peritoneal surface malignancy phenotype--a pilot immunohistochemical study of human pseudomyxoma peritonei and derived animal models","volume":"41","author":"Flatmark","year":"2010","journal-title":"Hum Pathol"},{"key":"10.1016\/j.ajpath.2025.08.005_bib54","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/S0002-9440(10)64211-3","article-title":"Pseudomyxoma peritonei is a disease of MUC2-expressing goblet cells","volume":"161","author":"O'Connell","year":"2002","journal-title":"Am J Pathol"},{"key":"10.1016\/j.ajpath.2025.08.005_bib55","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1245\/s10434-007-9778-9","article-title":"Pseudomyxoma peritonei: is disease progression related to microbial agents? a study of bacteria, MUC2 AND MUC5AC expression in disseminated peritoneal adenomucinosis and peritoneal mucinous carcinomatosis","volume":"15","author":"Semino-Mora","year":"2008","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.ajpath.2025.08.005_bib56","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1097\/01.MP.0000026617.52466.9F","article-title":"MUC2 is a molecular marker for pseudomyxoma peritonei","volume":"15","author":"O'Connell","year":"2002","journal-title":"Mod Pathol"},{"key":"10.1016\/j.ajpath.2025.08.005_bib57","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s12575-024-00239-0","article-title":"Breaking the mucin barrier: a new affinity chromatography-mass spectrometry approach to unveil potential cell markers and pathways altered in pseudomyxoma peritonei","volume":"26","author":"Romero-Ruiz","year":"2024","journal-title":"Biol Proced Online"},{"key":"10.1016\/j.ajpath.2025.08.005_bib58","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.humpath.2019.12.008","article-title":"Pathological prognostic factors of pseudomyxoma peritonei: comprehensive clinicopathological analysis of 155 cases","volume":"97","author":"Yan","year":"2020","journal-title":"Hum Pathol"},{"key":"10.1016\/j.ajpath.2025.08.005_bib59","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1111\/j.1440-1827.2007.02137.x","article-title":"MUC2, MUC5AC and MUC5B in the mucus of a patient with pseudomyxoma peritonei: biochemical and immunohistochemical study","volume":"57","author":"Mall","year":"2007","journal-title":"Pathol Int"},{"key":"10.1016\/j.ajpath.2025.08.005_bib60","doi-asserted-by":"crossref","first-page":"18","DOI":"10.7150\/ijms.16422","article-title":"Physical and chemical characteristics of mucin secreted by pseudomyxoma peritonei (PMP)","volume":"14","author":"Pillai","year":"2017","journal-title":"Int J Med Sci"},{"key":"10.1016\/j.ajpath.2025.08.005_bib61","doi-asserted-by":"crossref","first-page":"44","DOI":"10.4251\/wjgo.v2.i1.44","article-title":"Pseudomyxoma peritonei","volume":"2","author":"Bevan","year":"2010","journal-title":"World J Gastrointest Oncol"},{"issue":"Pt 3","key":"10.1016\/j.ajpath.2025.08.005_bib62","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1042\/bj2740679","article-title":"Effects of hydrogen peroxide, mild trypsin digestion and partial reduction on rat intestinal mucin and its disulphide-bound 118 kDa glycoprotein","volume":"274","author":"Mantle","year":"1991","journal-title":"Biochem J"},{"key":"10.1016\/j.ajpath.2025.08.005_bib63","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1042\/BST0370877","article-title":"Regulation of mucin expression in respiratory diseases","volume":"37","author":"Turner","year":"2009","journal-title":"Biochem Soc Trans"},{"key":"10.1016\/j.ajpath.2025.08.005_bib64","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1002\/ijc.28380","article-title":"A formulation for in situ lysis of mucin secreted in pseudomyxoma peritonei","volume":"134","author":"Pillai","year":"2014","journal-title":"Int J Cancer"},{"key":"10.1016\/j.ajpath.2025.08.005_bib65","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1515\/pp-2017-0013","article-title":"Assessment of a novel mucolytic solution for dissolving mucus in pseudomyxoma peritonei: an ex vivo and in vitro study","volume":"2","author":"Pillai","year":"2017","journal-title":"Pleura Peritoneum"},{"key":"10.1016\/j.ajpath.2025.08.005_bib66","doi-asserted-by":"crossref","first-page":"2107","DOI":"10.1074\/mcp.RA118.000615","article-title":"Glycomic profiling highlights increased fucosylation in pseudomyxoma peritonei","volume":"17","author":"Saarinen","year":"2018","journal-title":"Mol Cell Proteomics"},{"key":"10.1016\/j.ajpath.2025.08.005_bib67","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1159\/000536219","article-title":"Genome-wide analysis of DNA methylation in pseudomyxoma peritonei originated from appendiceal neoplasms","volume":"102","author":"Takane","year":"2024","journal-title":"Oncology"},{"key":"10.1016\/j.ajpath.2025.08.005_bib68","doi-asserted-by":"crossref","first-page":"32258","DOI":"10.1074\/jbc.M204862200","article-title":"Induction of MUC2 and MUC5AC mucins by factors of the epidermal growth factor (EGF) family is mediated by EGF receptor\/Ras\/Raf\/extracellular signal-regulated kinase cascade and Sp1","volume":"277","author":"Perrais","year":"2002","journal-title":"J Biol Chem"},{"key":"10.1016\/j.ajpath.2025.08.005_bib69","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1245\/s10434-012-2242-5","article-title":"Chronic anti-inflammatory drug therapy inhibits gel-forming mucin production in a murine xenograft model of human pseudomyxoma peritonei","volume":"19","author":"Choudry","year":"2012","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.ajpath.2025.08.005_bib70","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0179510","article-title":"Bilateral blockade of MEK- and PI3K-mediated pathways downstream of mutant KRAS as a treatment approach for peritoneal mucinous malignancies","volume":"12","author":"Kuracha","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.ajpath.2025.08.005_bib71","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/S0006-291X(02)02935-2","article-title":"Homeodomain protein CDX2 regulates goblet-specific MUC2 gene expression","volume":"300","author":"Yamamoto","year":"2003","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.ajpath.2025.08.005_bib72","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1038\/labinvest.2012.56","article-title":"Notch signaling pathway and Cdx2 expression in the development of Barrett's esophagus","volume":"92","author":"Tamagawa","year":"2012","journal-title":"Lab Invest"},{"key":"10.1016\/j.ajpath.2025.08.005_bib73","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.trsl.2015.03.004","article-title":"Mitogen-activated protein kinase inhibition reduces mucin 2 production and mucinous tumor growth","volume":"166","author":"Dilly","year":"2015","journal-title":"Transl Res"},{"key":"10.1016\/j.ajpath.2025.08.005_bib74","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.trsl.2015.10.006","article-title":"Targeting hypoxia-mediated mucin 2 production as a therapeutic strategy for mucinous tumors","volume":"169","author":"Dilly","year":"2016","journal-title":"Transl Res"},{"key":"10.1016\/j.ajpath.2025.08.005_bib75","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1158\/2159-8290.CD-20-1808","article-title":"Therapeutic targeting of the tumor microenvironment","volume":"11","author":"Bejarano","year":"2021","journal-title":"Cancer Discov"},{"key":"10.1016\/j.ajpath.2025.08.005_bib76","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2020.107753","article-title":"Tumor microenvironment as a therapeutic target in cancer","volume":"221","author":"Xiao","year":"2021","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.ajpath.2025.08.005_bib77","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1038\/nrc3581","article-title":"History of myeloid-derived suppressor cells","volume":"13","author":"Talmadge","year":"2013","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.ajpath.2025.08.005_bib78","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/j.ccr.2013.11.007","article-title":"Impeding macrophage entry into hypoxic tumor areas by Sema3A\/Nrp1 signaling blockade inhibits angiogenesis and restores antitumor immunity","volume":"24","author":"Casazza","year":"2013","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ajpath.2025.08.005_bib79","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1084\/jem.20050930","article-title":"B7-H4 expression identifies a novel suppressive macrophage population in human ovarian carcinoma","volume":"203","author":"Kryczek","year":"2006","journal-title":"J Exp Med"},{"key":"10.1016\/j.ajpath.2025.08.005_bib80","doi-asserted-by":"crossref","first-page":"1790","DOI":"10.3389\/fimmu.2019.01790","article-title":"Overexpression of PDE4A acts as checkpoint inhibitor against cAMP-mediated immunosuppression in vitro","volume":"10","author":"Schmetterer","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.ajpath.2025.08.005_bib81","doi-asserted-by":"crossref","first-page":"ra56","DOI":"10.1126\/scisignal.aaf0583","article-title":"Protein kinase A-dependent phosphorylation stimulates the transcriptional activity of hypoxia-inducible factor 1","volume":"9","author":"Bullen","year":"2016","journal-title":"Sci Signal"},{"key":"10.1016\/j.ajpath.2025.08.005_bib82","doi-asserted-by":"crossref","first-page":"3931","DOI":"10.1172\/JCI63170","article-title":"Dendritic cells tolerized with adenosine A(2)AR agonist attenuate acute kidney injury","volume":"122","author":"Li","year":"2012","journal-title":"J Clin Invest"},{"key":"10.1016\/j.ajpath.2025.08.005_bib83","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.canlet.2005.12.013","article-title":"COX-2 expression in pseudomyxoma peritonei","volume":"244","author":"Gatalica","year":"2006","journal-title":"Cancer Lett"},{"key":"10.1016\/j.ajpath.2025.08.005_bib84","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1016\/j.cell.2015.08.015","article-title":"Cyclooxygenase-dependent tumor growth through evasion of immunity","volume":"162","author":"Zelenay","year":"2015","journal-title":"Cell"},{"key":"10.1016\/j.ajpath.2025.08.005_bib85","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/j.semcancer.2022.02.010","article-title":"Metabolic modulation of immune checkpoints and novel therapeutic strategies in cancer","volume":"86","author":"Wang","year":"2022","journal-title":"Semin Cancer Biol"},{"key":"10.1016\/j.ajpath.2025.08.005_bib86","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1245\/s10434-013-3261-6","article-title":"Pseudomyxoma peritonei: inflammatory responses in the peritoneal microenvironment","volume":"21","author":"Lohani","year":"2014","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.ajpath.2025.08.005_bib87","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1016\/j.ejso.2015.04.005","article-title":"The role of baseline inflammatory-based scores and serum tumor markers to risk stratify pseudomyxoma peritonei patients treated with cytoreduction (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC)","volume":"41","author":"Kusamura","year":"2015","journal-title":"Eur J Surg Oncol"},{"key":"10.1016\/j.ajpath.2025.08.005_bib88","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1080\/02656736.2017.1384073","article-title":"The pre-operative neutrophil-lymphocyte ratio predicts overall and disease-free survival following cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with pseudomxyoma peritonei of appendiceal origin","volume":"34","author":"Rangarajan","year":"2018","journal-title":"Int J Hyperthermia"},{"key":"10.1016\/j.ajpath.2025.08.005_bib89","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1038\/nri1372","article-title":"Hydrophobicity: an ancient damage-associated molecular pattern that initiates innate immune responses","volume":"4","author":"Seong","year":"2004","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.ajpath.2025.08.005_bib90","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1126\/science.1071059","article-title":"The danger model: a renewed sense of self","volume":"296","author":"Matzinger","year":"2002","journal-title":"Science"},{"key":"10.1016\/j.ajpath.2025.08.005_bib91","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1002\/cam4.640","article-title":"Patient-derived xenograft mouse models of pseudomyxoma peritonei recapitulate the human inflammatory tumor microenvironment","volume":"5","author":"Kuracha","year":"2016","journal-title":"Cancer Med"},{"key":"10.1016\/j.ajpath.2025.08.005_bib92","doi-asserted-by":"crossref","first-page":"2819","DOI":"10.3390\/cancers13112819","article-title":"Anti-angiogenic treatment in pseudomyxoma peritonei-still a strong preclinical rationale","volume":"13","author":"Andersson","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ajpath.2025.08.005_bib93","first-page":"109","article-title":"Immunohistochemical features of the pseudomyxoma peritonei microenvironment an opportunity for clinicians","volume":"40","author":"Grizzi","year":"2018","journal-title":"Anal Quant Cytopathol Histopathol"},{"key":"10.1016\/j.ajpath.2025.08.005_bib94","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1186\/1750-1172-8-105","article-title":"A core microbiome associated with the peritoneal tumors of pseudomyxoma peritonei","volume":"8","author":"Gilbreath","year":"2013","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.ajpath.2025.08.005_bib95","doi-asserted-by":"crossref","first-page":"3966","DOI":"10.1158\/1078-0432.CCR-13-0616","article-title":"Antibiotic treatment decreases microbial burden associated with pseudomyxoma peritonei and affects beta-catenin distribution","volume":"19","author":"Semino-Mora","year":"2013","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ajpath.2025.08.005_bib96","doi-asserted-by":"crossref","first-page":"4007","DOI":"10.3390\/jcm12124007","article-title":"Under the hood: understanding the features of mucin in pseudomyxoma peritonei","volume":"12","author":"Villarejo-Campos","year":"2023","journal-title":"J Clin Med"},{"key":"10.1016\/j.ajpath.2025.08.005_bib97","doi-asserted-by":"crossref","first-page":"8836","DOI":"10.1158\/0008-5472.CAN-05-0718","article-title":"E-cadherin regulates the association between beta-catenin and actinin-4","volume":"65","author":"Hayashida","year":"2005","journal-title":"Cancer Res"},{"key":"10.1016\/j.ajpath.2025.08.005_bib98","first-page":"39","article-title":"Beta-catenin expression in human cancers","volume":"148","author":"Takayama","year":"1996","journal-title":"Am J Pathol"},{"key":"10.1016\/j.ajpath.2025.08.005_bib99","doi-asserted-by":"crossref","first-page":"285","DOI":"10.3390\/cancers3010285","article-title":"Enteric bacteria and cancer stem cells","volume":"3","author":"Sun","year":"2010","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ajpath.2025.08.005_bib100","doi-asserted-by":"crossref","first-page":"2420","DOI":"10.1038\/ajg.2010.281","article-title":"Mucolytic bacteria with increased prevalence in IBD mucosa augment in vitro utilization of mucin by other bacteria","volume":"105","author":"Png","year":"2010","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.ajpath.2025.08.005_bib101","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0076341","article-title":"Utilisation of mucin glycans by the human gut symbiont Ruminococcus gnavus is strain-dependent","volume":"8","author":"Crost","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.ajpath.2025.08.005_bib102","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1086\/368133","article-title":"Intracellular and interstitial expression of Helicobacter pylori virulence genes in gastric precancerous intestinal metaplasia and adenocarcinoma","volume":"187","author":"Semino-Mora","year":"2003","journal-title":"J Infect Dis"},{"key":"10.1016\/j.ajpath.2025.08.005_bib103","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.cbpc.2017.11.011","article-title":"Lipopolysaccharide impairs mucin secretion and stimulated mucosal immune stress response in respiratory tract of neonatal chicks","volume":"204","author":"Fan","year":"2018","journal-title":"Comp Biochem Physiol C Toxicol Pharmacol"},{"key":"10.1016\/j.ajpath.2025.08.005_bib104","doi-asserted-by":"crossref","first-page":"12930","DOI":"10.1073\/pnas.1406414111","article-title":"Pseudomonas aeruginosa triggers CFTR-mediated airway surface liquid secretion in swine trachea","volume":"111","author":"Luan","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.ajpath.2025.08.005_bib105","doi-asserted-by":"crossref","first-page":"5718","DOI":"10.1073\/pnas.95.10.5718","article-title":"Activation of NF-kappaB via a Src-dependent Ras-MAPK-pp90rsk pathway is required for Pseudomonas aeruginosa-induced mucin overproduction in epithelial cells","volume":"95","author":"Li","year":"1998","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.ajpath.2025.08.005_bib106","doi-asserted-by":"crossref","DOI":"10.1002\/jbt.23618","article-title":"Lixisenatide ameliorated lipopolysaccharide (LPS)-induced expression of mucin and inflammation in bronchial epithelial cells","volume":"38","author":"Xu","year":"2024","journal-title":"J Biochem Mol Toxicol"},{"key":"10.1016\/j.ajpath.2025.08.005_bib107","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1172\/JCI6097","article-title":"Allergen-induced IL-9 directly stimulates mucin transcription in respiratory epithelial cells","volume":"104","author":"Longphre","year":"1999","journal-title":"J Clin Invest"}],"container-title":["The American Journal of Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002944025003293?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002944025003293?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T13:51:28Z","timestamp":1773323488000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002944025003293"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":107,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["S0002944025003293"],"URL":"https:\/\/doi.org\/10.1016\/j.ajpath.2025.08.005","relation":{},"ISSN":["0002-9440"],"issn-type":[{"value":"0002-9440","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"From Theory to Practice","name":"articletitle","label":"Article Title"},{"value":"The American Journal of Pathology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajpath.2025.08.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 American Society for Investigative Pathology. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}